Page 2 - Oraquick Rapid News Today : Breaking News, Live Updates & Top Stories | Vimarsana

OraSure Technologies (NASDAQ:OSUR – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays […]

Analysts expect OraSure Technologies, Inc. (NASDAQ:OSUR – Get Rating) to announce $64.74 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for OraSure Technologies’ earnings, with the highest sales estimate coming in at $68.30 million and the lowest estimate coming in at $62.22 million. OraSure Technologies posted […]

Analysts forecast that OraSure Technologies, Inc. (NASDAQ:OSUR – Get Rating) will announce sales of $64.74 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for OraSure Technologies’ earnings, with the lowest sales estimate coming in at $62.22 million and the highest estimate coming in at $68.30 million. OraSure […]

Shares of OraSure Technologies, Inc. (NASDAQ:OSUR – Get Rating) have been given an average recommendation of “Hold” by the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the […]

Lucid Diagnostics (NASDAQ:LUCD – Get Rating) and OraSure Technologies (NASDAQ:OSUR – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Analyst Ratings This is a summary of current ratings […]